login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

FDA advisory committee votes against approval of rivaroxaban for acute coronary syndrome


Thursday, 24 May 2012 12:04



On 23 May, the FDA’s Cardiovascular and Renal Drugs advisory committee voted six to four, with one abstention, against the approval of the oral anticoagulant rivaroxaban (Xarelto, Bayer Healthcare/Jansen Pharmaceuticals) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome in combination with standard antiplatelet therapy (aspirin with or without clopidogrel). 


Data from the pivotal phase 3 ATLAS ACS 2 TIMI 51 (Anti-Xa therapy to lower cardiovascular events in addition to aspirin with/without thienopyridine therapy in subjects with acute coronary syndrome) supported rivaroxaban’s new indication. Results from the study showed that rivaroxaban given in combination with standard antiplatelet therapy were superior to standard therapy alone in preventing secondary cardiovascular events in patients with acute coronary syndrome. There were also low rates of major bleeding events in coronary artery bypass graft (CABG) surgery. Despite these results, the FDA’s panel voted against based on missing data on early patient withdrawals.

The FDA assigned a priority review designation to the supplemental new drug application filed on 29 December 2011 for rivaroxaban in patients with acute coronary syndrome. Recommendations from the advisory committee will be considered by the FDA in its review, but the FDA is not required to follow them.

Rivaroxaban is currently approved in the USA to reduce the risk of blood clots in the legs and lungs of people who have just had knee or hip replacement surgery, and to reduce the risk of both haemorrhagic and thrombotic strokes as well as other blood clots in people with atrial fibrillation not caused by a heart valve problem.




Add New Comment

Related Items


Most popular


Mind the gender gap: Addressing inequalities in interventional cardiology
Monday, 14 Dec 2015
With only 4.5% of US interventional cardiologists being female, Cardiovascular News reviews the steps being taken to ensure that being female is not a barrier to being an interventional cardiologist. Mind the gender gap: Addressing inequalities in interventional cardiology

US cardiovascular societies publish joint expert consensus on left atrial appendage occlusion requirements
Friday, 11 Dec 2015
SCAI, ACC, and HRS have published a joint document providing recommendations for the establishment and maintenance of left atrial appendage occlusion programmes performing LAA closure. US cardiovascular societies publish joint expert consensus on left atrial appendage occlusion requirements

Vascular Dynamics’ MobiusHD system receives CE mark for the treatment of resistant hypertension
Wednesday, 06 Jan 2016
The MobiusHD minimally invasive system from Vascular Dynamics has been granted CE mark approval for the treatment of resistant hypertension. Vascular Dynamics’ MobiusHD system receives CE mark for the treatment of resistant hypertension

Features


Building the ideal heart team for transcatheter mitral valve interventions
Monday, 08 Feb 2016
In this commentary, Vinayak Bapat outlines transcatheter mitral valve interventions and reviews which specialists should comprise the optimal heart team for such procedures. Building the ideal heart team for transcatheter mitral valve interventions

Training is the key to wider adoption of the transradial approach for PCI in the USA
Monday, 25 Jan 2016
This commentary explores why the USA, despite the data supporting the transradial approach, has been more reluctant than other countries to adopt the approach. Training is the key to wider adoption of the transradial approach for PCI in the USA

Profiles


Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Javier Escaned
Wednesday, 02 Sep 2015
Javier Escaned (head of Section, Interventional Cardiology Unit, Hospital Clinico San Carlos, M... Javier Escaned

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions